Details for Patent: 11,452,692
✉ Email this page to a colleague
Which drugs does patent 11,452,692 protect, and when does it expire?
Patent 11,452,692 protects COBENFY and is included in one NDA.
Drugs Protected by US Patent 11,452,692
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-001 | Sep 26, 2024 | RX | Yes | No | 11,452,692 | ⤷ Subscribe | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Subscribe | ||||
Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-002 | Sep 26, 2024 | RX | Yes | No | 11,452,692 | ⤷ Subscribe | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Subscribe | ||||
Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-003 | Sep 26, 2024 | RX | Yes | Yes | 11,452,692 | ⤷ Subscribe | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |